Table 3.
Use of thromboprophylaxis according to Padua prediction score
| Patients who should receive thrombopro-phylaxis | Patients who should not receive thromboprophylaxis | Patients who received thrombo-prophylaxis | Patients who did not receive thrombopro-phylaxis despite indication | Patients received thromboprophylaxis without indication | p-value | |
|---|---|---|---|---|---|---|
| Padua prediction score ≥ 4 points, n (%) | 39 (7.8) | 459 (92.2) | 28 (5.6) | 11 (2.2) | 391 (78.5) | < 0.001 |
| The histopathological type of cancer, n (%) | ||||||
| Squamous-cell cancer | 7 (17.9) | 100 (21.8) | 93 (22.2) | 2 (18.2) | 88 (22.5) | 0.80 |
| Lung adenocarcinoma | 15 (38.5) | 178 (38.8) | 167 (39.9) | 4 (36,4) | 156 (39.9) | 0.97 |
| Small-cell lung cancer | 15 (38.5) | 110 (23.9) | 98 (23.4) | 5 (45.4) | 88 (22.5) | 0.06 |
| Mesothelioma | 0 (0.0) | 2 (0.4) | 2 (0.5) | 0 (0.0) | 2 (0.5) | 0.90 |
| NOS | 2 (5.1) | 45 (9.8) | 39 (9.3) | 0 (0.0) | 37 (9.5) | 0.06 |
| Other cancers | 0 (0.0) | 24 (5.2) | 20 (4.8) | 0 (0.0) | 20 (5.1) | 0.35 |
| The stage of cancer, n (%) | ||||||
| I | 0 (0.0) | 1 (0.2) | 1 (0.2) | 0 (0.0) | 1 (0,2) | 0.95 |
| II | 1 (2.6) | 13 (2.8) | 11 (2.6) | 0 (0.0) | 10 (2.5) | 0.81 |
| III | 12 (30.8) | 149 (32.5) | 145 (34.6) | 4 (36.4) | 137 (35.1) | 0.78 |
| IV | 26 (66.7) | 296 (64.5) | 262 (62.5) | 7 (63.6) | 243 (62.1) | 0.83 |
Data are presented number (percentage)